Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AT-1501-K207: BESTOW: a Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Next Previous
Trial Profile

AT-1501-K207: BESTOW: a Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Corticosteroids; Mycophenolate; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms BESTOW
  • Sponsors Eledon Pharmaceuticals

Most Recent Events

  • 12 Nov 2024 According to an Eledon Pharmaceuticals media release, the increase in R&D expenses in 2024, compared to 2023, was driven by a rise in clinical development expenses related to the Phase 1b and Phase 2 BESTOW studies, an increase in employee compensation and benefits related to increased headcount, and greater chemistry, manufacturing and controls (CMC) expenses related to the production of clinical trial materials.
  • 04 Sep 2024 According to an Eledon Pharmaceuticals media release, the company anticipate reporting top-line results for the BESTOW trial in the fourth quarter of 2025.
  • 04 Sep 2024 According to an Eledon Pharmaceuticals media release, the company has successfully completed enrollment for its Phase 2 BESTOW clinical trial. Enrollment completed four months ahead of schedule.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top